JP7897796B2 - 感染症の治療又は発症を制限するためのポリペプチド、組成物、及びそれらの使用 - Google Patents

感染症の治療又は発症を制限するためのポリペプチド、組成物、及びそれらの使用

Info

Publication number
JP7897796B2
JP7897796B2 JP2022548783A JP2022548783A JP7897796B2 JP 7897796 B2 JP7897796 B2 JP 7897796B2 JP 2022548783 A JP2022548783 A JP 2022548783A JP 2022548783 A JP2022548783 A JP 2022548783A JP 7897796 B2 JP7897796 B2 JP 7897796B2
Authority
JP
Japan
Prior art keywords
rbd
sars
cov
nanoparticles
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513720A5 (cg-RX-API-DMAC7.html
JP2023513720A (ja
Inventor
キング,ニール,ピー.
ヴィ―スラー,デイヴィット
ウォーキー,カール
ウォールズ,アレクサンドラ,シー.
ワン,ジン,ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of JP2023513720A publication Critical patent/JP2023513720A/ja
Publication of JP2023513720A5 publication Critical patent/JP2023513720A5/ja
Application granted granted Critical
Publication of JP7897796B2 publication Critical patent/JP7897796B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2022548783A 2020-02-14 2021-02-12 感染症の治療又は発症を制限するためのポリペプチド、組成物、及びそれらの使用 Active JP7897796B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
US62/977,036 2020-02-14
US202063046159P 2020-06-30 2020-06-30
US63/046,159 2020-06-30
US202063064235P 2020-08-11 2020-08-11
US63/064,235 2020-08-11
PCT/US2021/017799 WO2021163438A1 (en) 2020-02-14 2021-02-12 Polypeptides, compositions, and their use to treat or limit development of an infection

Publications (3)

Publication Number Publication Date
JP2023513720A JP2023513720A (ja) 2023-04-03
JP2023513720A5 JP2023513720A5 (cg-RX-API-DMAC7.html) 2024-02-19
JP7897796B2 true JP7897796B2 (ja) 2026-07-30

Family

ID=74873805

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548783A Active JP7897796B2 (ja) 2020-02-14 2021-02-12 感染症の治療又は発症を制限するためのポリペプチド、組成物、及びそれらの使用

Country Status (13)

Country Link
US (1) US20240277831A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103230A1 (cg-RX-API-DMAC7.html)
JP (1) JP7897796B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220142472A (cg-RX-API-DMAC7.html)
CN (1) CN116096404A (cg-RX-API-DMAC7.html)
AU (1) AU2021221139A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016220A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167318A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011467A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022009860A (cg-RX-API-DMAC7.html)
PE (1) PE20230301A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552099A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021163438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US11192940B2 (en) 2020-04-10 2021-12-07 Adagio Therapeutics, Inc. Compounds specific to coronavirus S protein and uses thereof
US20220016268A1 (en) * 2020-07-17 2022-01-20 Tonix Pharmaceuticals Holding Corp. Skin-based testing for detection of cell-mediated immune responses to sars-cov-2
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
US20220324918A1 (en) * 2021-03-30 2022-10-13 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF
WO2023034991A1 (en) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Mrna vaccine formulations and methods of using the same
WO2023039540A2 (en) * 2021-09-10 2023-03-16 Jacobs Technion-Cornell Institute Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions
KR102621026B1 (ko) * 2021-10-15 2024-01-09 에스케이바이오사이언스(주) 단백질의 정제방법
KR102527221B1 (ko) * 2021-10-15 2023-05-02 에스케이바이오사이언스 주식회사 단백질의 정제방법
KR102524839B1 (ko) * 2021-11-04 2023-04-25 에스케이바이오사이언스(주) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
US20250000968A1 (en) * 2021-11-12 2025-01-02 The United States of America, as represented by the Secretary,Department of Health and Human Service Sars-cov-2 spike fused to a hepatitis b surface antigen
WO2023122257A2 (en) * 2021-12-22 2023-06-29 La Jolla Institute For Immunology Coronavirus spike glycoprotein with improved expression and stability
CN114656571B (zh) * 2022-02-18 2024-07-16 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用
US20240207389A1 (en) * 2022-04-27 2024-06-27 Northwestern University Methods for improving covid vaccine immunogenicity
KR102689037B1 (ko) * 2022-07-12 2024-07-30 에스케이바이오사이언스 주식회사 SARS-CoV-2 백신 부스터 조성물
KR20250084945A (ko) * 2022-10-05 2025-06-11 유니버시티 오브 워싱턴 범사르베코바이러스 나노입자 백신
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160122392A1 (en) 2014-11-03 2016-05-05 University Of Washington Polypeptides for use in self-assembling protein nanostructures
JP2016539944A (ja) 2013-11-26 2016-12-22 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 新規sars免疫原性組成物
WO2018187325A1 (en) 2017-04-04 2018-10-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016639A2 (en) * 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
US10248758B2 (en) * 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
WO2017046801A1 (en) * 2015-09-17 2017-03-23 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
WO2018175560A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
CN112088014B (zh) * 2018-02-28 2026-03-24 华盛顿大学 自组装纳米结构疫苗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539944A (ja) 2013-11-26 2016-12-22 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 新規sars免疫原性組成物
US20160122392A1 (en) 2014-11-03 2016-05-05 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2018187325A1 (en) 2017-04-04 2018-10-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Accession No.MN908947.1,Database Genbank,2020年01月12日,<URL: https://www.ncbi.nlm.nih.gov/nuccore/MN908947.1>,[検索日:2025年03月28日]

Also Published As

Publication number Publication date
EP4103230A1 (en) 2022-12-21
PE20230301A1 (es) 2023-02-13
WO2021163438A1 (en) 2021-08-19
MX2022009860A (es) 2022-11-07
CO2022011467A2 (es) 2022-10-31
KR20220142472A (ko) 2022-10-21
BR112022016220A2 (pt) 2022-10-25
JP2023513720A (ja) 2023-04-03
PH12022552099A1 (en) 2024-01-29
CA3167318A1 (en) 2021-08-19
CN116096404A (zh) 2023-05-09
US20240277831A1 (en) 2024-08-22
AU2021221139A1 (en) 2022-09-01

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260717

R150 Certificate of patent or registration of utility model

Ref document number: 7897796

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150